Associations of daily walking activity with biomarkers related to cardiac distress in patients with chronic obstructive pulmonary disease

Respiration

Volumn 85, Issue 3, 2013, Pages 195-202

  Jehn, Melissa ^a,d,e   Schindler, Christian ^b   Meyer, Anja ^c   Tamm, Michael ^c   Koehler, Friedrich ^d   Witt, Christian ^e   Schmidt Trucksäss, Arno ^a   Stolz, Daiana ^c  

^a UNIVERSITY OF BASEL   (Switzerland)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d Centre for Cardiovascular Telemedicine   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Accelerometry; Biomarkers; Dyspnea; Exercise capacity; Walking intensity

Indexed keywords

BIOLOGICAL MARKER; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MIDREGIONAL PROATRIAL NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; PROADRENOMEDULLIN; UNCLASSIFIED DRUG; BRAIN NATRIURETIC PEPTIDE;

ACCELEROMETRY; ADULT; AGED; ARTICLE; CHARLSON COMORBIDITY INDEX; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HEART DISEASE; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; WALKING; CHARLSON SCORE; COHORT ANALYSIS; DAILY LIFE ACTIVITY; GROUPS BY AGE; HEART HEMODYNAMICS; MODIFIED MEDICAL RESEARCH COUNCIL DYSPNEA SCALE; PROGNOSIS; RATING SCALE; SAINT GEORGES RESPIRATORY QUESTIONNAIRE TOTAL SCORE; SCORING SYSTEM;

ACCELEROMETRY; ADRENOMEDULLIN; AGED; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; RISK ASSESSMENT; WALKING;

EID: 84875216054     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000345218     Document Type: Article

References (46)

1. Mannino DM, Buist AS: Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765-773.
2. Buist AS, McBurnie MA, Vollmer WM, Gil-lespie S, Burney P, Mannino DM, et al: International variation in the prevalence of COPD (the BOLD Study): a population-based prev-a lence study. Lancet 2007; 370: 741-750.
3. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
4. Berry CE, Wise RA: Mortality in COPD: causes, risk factors, and prevention. COPD 2010; 7: 375-382.
5. Sin DD, Man SF: Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2:8-11.
6. van Gestel YRBM, Flu WJ, van Kuijk J, Hoeks SE, Bax JJ, Sin DD, et al: Association of COPD with carotoid wall intima-media thickness. Respiratory Medicine 2010; 104: 712-716.
7. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al: Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184: 662-671.
8. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, et al: Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:867-874.
9. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, et al: Co-peptin, C-reactive protein, and procalcito-nin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131: 1058-1067.
10. Waschki B, Kirsten A, Holz O, Muller KC, Meyer T, Watz H, et al: Physica l activ it y is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011; 140:331-342.
11. Bernasconi M, Tamm M, Bingisser R, Miedinger D, Leuppi J, Muller B, et al: Midregional proatrial natriuretic peptide predicts survival in exacerbations of COPD. Chest 2011; 140:91-99.
12. Stolz D, Christ-Crain M, Morgenthaler NG, Miedinger D, Leuppi J, Mueller C, et al: Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest 2008; 134: 263-272.
13. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM: Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006; 61:772-778.
14. Garcia-Rio F, Rojo B, Casitas R, Lores V, Madero R, Romero D, et al: Prognostic value of the objective measurement of daily physical activity in COPD patients. Chest 2012; 142: 388-346.
15. Bourbeau J, van der Palen J: Promoting effective self-management programmes to improve COPD. Eur Respir J 2009; 33:461-463.
16. Celli BR, Cote CG, Marin JM, Casanova C, Montes de OM, Mendez RA, et al: The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012.
17. Jehn M, Schindler C, Meyer A, Tamm M, Schmidt-Trucksass A, Stolz D: Daily walking intensity as a predictor of quality of life in patients with COPD. Med Sci Sports Exerc 2012; 44: 1212-1218.
18. Watz H, Waschki B, Meyer T, Magnussen H: Physical activity in patients with COPD. Eur Respir J 2009; 33: 262-272.
19. Jehn M, Schmidt-Trucksass A, Meyer A, Schindler C, Tamm M, Stolz D: Association of daily physical activity volume and intensity with COPD severity. Respir Med 2011; 105:1846-1852.
20. Moy ML, Matthess K, Stolzmann K, Reilly J, Garshick E: Free-living physical activity in COPD: assessment with accelerometer and activity checklist. J Rehabil Res Dev 2009; 46: 277-286.
21. Nguyen HQ, Steele B, Benditt JO: Use of ac-celerometers to characterize physical activity patterns with COPD exacerbations. Int J Chron Obstruct Pulmon Dis 2006; 1:455-460.
22. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R: Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 972-977.
23. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R: Quantifying physical activity in daily life with questionnaires and motion sensors in COPD. Eur Respir J 2006; 27:1040-1055.
24. Soler-Cataluna JJ, Martinez-Garcia MA, Roman SP, Salcedo E, Navarro M, Ochando R: Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60:925-931.
25. Benzo RP, Chang CC, Farrell MH, Kaplan R, Ries A, Martinez FJ, et al: Physical activity, health status and risk of hospitalization in patients with severe chronic obstructive pulmonary disease. Respiration 2010; 80:10-18.
26. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM: Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006; 61:772-778.
27. Garcia-Rio F, Rojo B, Casitas R, Lores V, Madero R, Romero D, et al: Prognostic value of the objective measurement of daily physical activity in COPD patients. Chest 2012; 142: 338-346.
28. Soler-Cataluna JJ, Martinez-Garcia MA, Roman SP, Salcedo E, Navarro M, Ochando R: Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60:925-931.
29. Stolz D: PRedicting outcome using systemic markers in severe exacerbations of chronic obstructive pulmonary disease (COPD): the PROMISE-COPD cohort study. Controlled Clinical Trial Website. http://www.con-trolled-trials. com/ISRCTN99586989/Stolz.
30. Rabe K F, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Ca re Med 2007; 176: 532-555.
31. Barr JT, Schumacher GE, Freeman S, Le-Moine M, Bakst AW, Jones PW: American translation, modification, and validation of the St. George's Respiratory Questionnaire. Clin Ther 2000; 22:1121-1145.
32. Morgenthaler NG, Struck J, Thomas B, Bergmann A: Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004; 50: 234-236.
33. Morgenthaler NG, Struck J, Alonso C, Bergmann A: Measurement of midregional pro-adrenomedu l lin in plasma w it h an immuno-luminometric assay. Clin Chem 2005; 51: 1823-1829.
34. Jehn M, Schmidt-Trucksaess A, Schuster T, Hanssen H, Weis M, Halle M, et al: Accel-erometer-based quantification of 6-minute walk test performance in patients with chronic heart failure: applicability in tele-medicine. J Card Fail 2009; 15:334-340.
35. Jehn M, Schmidt-Trucksass A, Schuster T, Weis M, Hanssen H, Halle M, et al: Daily walking performance as an independent predictor of advanced heart failure: prediction of exercise capacity in chronic heart failure. Am Heart J 2009; 157:292-298.
36. Anker SD, Koehler F, Abraham WT: Tele-medicine and remote management of patients with heart failure. Lancet 2011; 378: 731-739.
37. Koehler F, Winkler S, Schieber M, Sechtem U, Stangl K, Bohm M, et al: Telemedical interventional monitoring in heart failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of tele-medicine on mortality in ambulatory patients with heart failure: study design. Eur J Heart Fail 2010; 12:1354-1362.
38. Koehler F, Winkler S, Schieber M, Sechtem U, Stangl K, Bohm M, et al: Impac t of remote telemedical management on mortality and hospitalizations in a mbu lator y patients with chronic heart failure: the telemedical inter-ventional monitoring in heart failure study. Circulation 2011; 123:1873-1880.
39. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, et al: Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010; 55:2062-2076.
40. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA: Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thora x 2007; 62: 411-415.
41. Yu CM, Cheung BM, Leung R, Wang Q, Lai WH, Lau CP: Increase in plasma adreno-medullin in patients with heart failure characterised by diastolic dysfunction. Heart 2001; 86:155-160.
42. Watz H, Waschki B, Boehme C, Claussen M, Meyer T, Magnussen H: Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med 2008; 177: 743-751.
43. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R: Physical activity and hospitalization for exacerbation of COPD. Chest 2006; 129: 536-644.
44. Steele BG, Holt L, Belza B, Ferris S, Lak shmi-naryan S, Buchner DM: Quantitating physical activity in COPD using a triaxial acceler-ometer. Chest 2000; 117:1359-1367.
45. Troosters T, Sciurba F, Battaglia S, Langer D, Valluri SR, Martino L, et al: Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir Med 2010; 104:1005-1011.
46. Watz H, Waschki B, Meyer T, Magnussen H: Physical activity in patients with COPD. Eur Respir J 2009; 33: 262-272.